Bimagrumab
- Generic Name
- Bimagrumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1356922-05-8
- Unique Ingredient Identifier
- N15SW1DIV8
- Background
Bimagrumab has been used in trials studying the treatment and supportive care of Sarcopenia, Skeletal Muscle, Mechanical Ventilation, Sporadic Inclusion Body Myositis, and Sporadic Inclusion Body Myositis (sIBM), among others.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
- Conditions
- Interventions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 140
- Registration Number
- NCT06643728
- Locations
- πΊπΈ
Eastside Research Associates, Redmond, Washington, United States
πΊπΈPinnacle Research Group, LLC, Anniston, Alabama, United States
πΊπΈCentral Research Associates, Birmingham, Alabama, United States
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
- Conditions
- Interventions
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 507
- Registration Number
- NCT05616013
- Locations
- πΊπΈ
Pinnacle Research Group, LLC, Anniston, Alabama, United States
πΊπΈCullman Clinical Trials, Cullman, Alabama, United States
πΊπΈIndago Research & Health Center, Inc, Hialeah, Florida, United States
An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
- Conditions
- Interventions
- First Posted Date
- 2015-10-09
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 211
- Registration Number
- NCT02573467
- Locations
- π¬π§
Novartis Investigative Site, Newcastle upon Tyne, United Kingdom
A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study
- First Posted Date
- 2015-06-11
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 160
- Registration Number
- NCT02468674
- Locations
- π¨π³
Novartis Investigative Site, Taipei, Taiwan
Dose Range Finding Study of Bimagrumab in Sarcopenia
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 217
- Registration Number
- NCT02333331
- Locations
- π¨π³
Novartis Investigative Site, Taipei, Taiwan
Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
- Conditions
- Interventions
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2020-08-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 251
- Registration Number
- NCT02152761
- Locations
- π¬π§
Novartis Investigative Site, Bath, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.